PE20212271A1 - Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1 - Google Patents

Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1

Info

Publication number
PE20212271A1
PE20212271A1 PE2021001680A PE2021001680A PE20212271A1 PE 20212271 A1 PE20212271 A1 PE 20212271A1 PE 2021001680 A PE2021001680 A PE 2021001680A PE 2021001680 A PE2021001680 A PE 2021001680A PE 20212271 A1 PE20212271 A1 PE 20212271A1
Authority
PE
Peru
Prior art keywords
seq
antagonists
combinations
ildr2
cdr
Prior art date
Application number
PE2021001680A
Other languages
English (en)
Inventor
Lars Rose
Uwe Gritzan
Spencer Liang
Andrew Pow
John Hunter
Ofer Levy
Ilan Vaknin
Original Assignee
Bayer Ag
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Compugen Ltd filed Critical Bayer Ag
Publication of PE20212271A1 publication Critical patent/PE20212271A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

SE REFIERE A UN ANTICUERPO ANTI-ILDR2 O UN FRAGMENTO DEL MISMO QUE COMPRENDE LAS TRES SECUENCIAS DE CADENA PESADA DE CDR DE ACUERDO CON LAS SEC ID NO:1, SEC ID NO:2 Y SEC ID NO:3 Y LAS TRES SECUENCIAS DE CADENA LIGERA DE CDR DE ACUERDO CON LAS SEC ID NO:4, SEC ID NO:5 Y SEC ID NO:6. TAMBIEN SE REFIERE A UNA COMBINACION QUE COMPRENDE A) UN ANTICUERPO ANTI-ILDR2 O UN FRAGMENTO DEL MISMO, Y B) UN ANTAGONISTA DE PD-1 TAL COMO NIVOLUMAB O PEMBROLIZUMAB. DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DE CANCER.
PE2021001680A 2019-04-11 2020-04-06 Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1 PE20212271A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832320P 2019-04-11 2019-04-11
PCT/EP2020/059745 WO2020207961A1 (en) 2019-04-11 2020-04-06 Combinations of anti-ildr2 antibodies and pd-1 antagonists

Publications (1)

Publication Number Publication Date
PE20212271A1 true PE20212271A1 (es) 2021-11-30

Family

ID=70224379

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001680A PE20212271A1 (es) 2019-04-11 2020-04-06 Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1

Country Status (14)

Country Link
US (1) US20220169736A1 (es)
EP (1) EP3952910A1 (es)
JP (1) JP2022528472A (es)
KR (1) KR20210151808A (es)
CN (1) CN113645999A (es)
AR (1) AR118621A1 (es)
AU (1) AU2020271352A1 (es)
CA (1) CA3136510A1 (es)
IL (1) IL287093A (es)
MX (1) MX2021012406A (es)
PE (1) PE20212271A1 (es)
SG (1) SG11202109623WA (es)
TW (1) TW202104275A (es)
WO (1) WO2020207961A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2439273T (lt) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
US8415455B2 (en) 2007-09-04 2013-04-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
AU2013216320A1 (en) * 2012-02-01 2014-04-03 Compugen Ltd. C10RF32 antibodies, and uses thereof for treatment of cancer
US11655297B2 (en) * 2017-11-30 2023-05-23 Bayer Aktiengesellschaft ILDR2 antagonists and combinations thereof

Also Published As

Publication number Publication date
IL287093A (en) 2021-12-01
EP3952910A1 (en) 2022-02-16
SG11202109623WA (en) 2021-10-28
KR20210151808A (ko) 2021-12-14
MX2021012406A (es) 2022-01-19
WO2020207961A1 (en) 2020-10-15
AR118621A1 (es) 2021-10-20
CA3136510A1 (en) 2020-10-15
TW202104275A (zh) 2021-02-01
AU2020271352A8 (en) 2022-04-07
US20220169736A1 (en) 2022-06-02
CN113645999A (zh) 2021-11-12
JP2022528472A (ja) 2022-06-10
AU2020271352A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
PE20150002A1 (es) Anticuerpos anti-fcrn
CO2020009861A2 (es) Inhibidores pd-1/pd-l1
PH12016502590A1 (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
CU24568B1 (es) Anticuerpo inhibidor de masp-3
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
PE20190208A1 (es) Anticuerpos que reconocen tau
CL2017001920A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
PE20191347A1 (es) Anticuerpos procoagulantes
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
PE20190398A1 (es) Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos
PE20171653A1 (es) Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b
CO2019013935A2 (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
PE20170908A1 (es) VARIANTES DE INTERFERON a2b
UY37834A (es) Tratamiento de mh con compuestos de pirimidinadiona
CO6700829A2 (es) Moduladores novedosos y métodos de uso
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
DOP2019000064A (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
PE20200734A1 (es) Anticuerpos anti-tgf-beta y su uso
PE20161210A1 (es) Anticuerpos anti-mcam y metodos de uso asociados
DOP2018000284A (es) Anticuerpos antifactor de la coagulación xi
PE20230381A1 (es) Proteina de union a rgma
EA202091557A1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd22